MX2022006783A - Nuevos derivados de metilquinazolinona. - Google Patents
Nuevos derivados de metilquinazolinona.Info
- Publication number
- MX2022006783A MX2022006783A MX2022006783A MX2022006783A MX2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A MX 2022006783 A MX2022006783 A MX 2022006783A
- Authority
- MX
- Mexico
- Prior art keywords
- methylquinazolinone
- derivatives
- new
- compound
- formula
- Prior art date
Links
- RLLNOZZVLWEBBI-UHFFFAOYSA-N 4-methyl-3h-quinazolin-2-one Chemical class C1=CC=CC2=C(C)NC(=O)N=C21 RLLNOZZVLWEBBI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Combines (AREA)
- Harvester Elements (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006783A true MX2022006783A (es) | 2022-07-11 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006783A MX2022006783A (es) | 2019-12-10 | 2020-12-08 | Nuevos derivados de metilquinazolinona. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (OSRAM) |
| EP (2) | EP4483882A3 (OSRAM) |
| JP (2) | JP7108146B2 (OSRAM) |
| KR (1) | KR102836833B1 (OSRAM) |
| CN (2) | CN114787156B (OSRAM) |
| AR (1) | AR122351A1 (OSRAM) |
| AU (1) | AU2020403443B2 (OSRAM) |
| CA (1) | CA3162883A1 (OSRAM) |
| CL (1) | CL2022001529A1 (OSRAM) |
| CO (1) | CO2022008968A2 (OSRAM) |
| CR (1) | CR20220251A (OSRAM) |
| DK (1) | DK4073065T3 (OSRAM) |
| ES (1) | ES3023264T3 (OSRAM) |
| FI (1) | FI4073065T3 (OSRAM) |
| HR (1) | HRP20250418T1 (OSRAM) |
| HU (1) | HUE071148T2 (OSRAM) |
| IL (2) | IL292161B2 (OSRAM) |
| LT (1) | LT4073065T (OSRAM) |
| MA (1) | MA58087B1 (OSRAM) |
| MX (1) | MX2022006783A (OSRAM) |
| NZ (1) | NZ787393A (OSRAM) |
| PE (1) | PE20221778A1 (OSRAM) |
| PH (1) | PH12022551119A1 (OSRAM) |
| PL (1) | PL4073065T3 (OSRAM) |
| PT (1) | PT4073065T (OSRAM) |
| RS (1) | RS66721B1 (OSRAM) |
| SI (1) | SI4073065T1 (OSRAM) |
| TW (1) | TWI877268B (OSRAM) |
| UA (1) | UA128299C2 (OSRAM) |
| WO (1) | WO2021116055A1 (OSRAM) |
| ZA (2) | ZA202204675B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102836833B1 (ko) * | 2019-12-10 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 신규 메틸퀴나졸리논 유도체 |
| KR20220112777A (ko) * | 2019-12-10 | 2022-08-11 | 에프. 호프만-라 로슈 아게 | 패러독스 파괴제로서의 새로운 braf 억제제 |
| CN116096710B (zh) | 2020-06-09 | 2025-07-25 | 阿雷生物药品公司 | 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物 |
| EP4351583A4 (en) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | THERAPEUTICS TO DEGRADE MUTANT BRAF |
| TW202313046A (zh) * | 2021-06-09 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 用於癌症治療之組合療法 |
| AU2022289684A1 (en) * | 2021-06-09 | 2023-10-05 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CA3222612A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
| JPWO2023008462A1 (OSRAM) | 2021-07-27 | 2023-02-02 | ||
| AU2022383040A1 (en) | 2021-11-04 | 2024-03-07 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| WO2024105144A1 (en) | 2022-11-18 | 2024-05-23 | F. Hoffmann-La Roche Ag | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
| EP4634172A1 (en) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Combination therapy for cancer treatment |
| EP4634171A1 (en) * | 2022-12-15 | 2025-10-22 | F. Hoffmann-La Roche AG | Process for the preparation of a quinazolinone derivative |
| AU2024289011A1 (en) | 2023-07-04 | 2025-12-18 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| PT2947072T (pt) | 2008-03-17 | 2016-12-06 | Ambit Biosciences Corp | 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| JP6186440B2 (ja) | 2012-09-19 | 2017-08-23 | ノバルティス アーゲー | キナーゼ阻害剤としてのジヒドロピロリジノピリミジン |
| BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
| WO2016191296A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
| SI3359541T1 (sl) | 2015-10-09 | 2021-01-29 | Abbvie Overseas S.A R.L. | N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| TWI748317B (zh) | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并－嘧啶酮與喋啶酮化合物及使用方法 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| KR102836833B1 (ko) | 2019-12-10 | 2025-07-22 | 에프. 호프만-라 로슈 아게 | 신규 메틸퀴나졸리논 유도체 |
| KR20220112777A (ko) | 2019-12-10 | 2022-08-11 | 에프. 호프만-라 로슈 아게 | 패러독스 파괴제로서의 새로운 braf 억제제 |
| CN116096710B (zh) | 2020-06-09 | 2025-07-25 | 阿雷生物药品公司 | 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物 |
| JP2023554062A (ja) | 2020-12-18 | 2023-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規アリール－ピリド－ピリミジン－オン誘導体 |
| EP4263518A1 (en) | 2020-12-18 | 2023-10-25 | F. Hoffmann-La Roche AG | New quinazolinone derivatives |
| EP4351583A4 (en) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | THERAPEUTICS TO DEGRADE MUTANT BRAF |
| JP2024545073A (ja) | 2021-12-08 | 2024-12-05 | アレイ バイオファーマ インコーポレイテッド | Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態 |
-
2020
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 CA CA3162883A patent/CA3162883A1/en active Pending
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 NZ NZ787393A patent/NZ787393A/en unknown
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
-
2021
- 2021-12-14 JP JP2021202780A patent/JP2022124458A/ja active Pending
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| PH12020500673A1 (en) | Compounds | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201990952A1 (ru) | ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MX2016014939A (es) | Derivados de carboxamida. | |
| BR112018074985A2 (pt) | composições antibacterianas | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX379576B (es) | Derivados de azetidina | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| ZA202205170B (en) | Process and intermediate for the preparation of oxetan-2-ylmethanamine | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EA202190458A1 (ru) | Составы, содержащие дендример | |
| MY208423A (en) | Composition of aminopyran derivative | |
| EA202190707A1 (ru) | Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы |